薛松林
安斯泰来公司 全球药物警戒负责人

  薛松林二十多年以来就职于数家大型国际医药公司,包括 Roche(罗氏),Pfizer(辉瑞), Novartis (诺华),Takeda(武田)从事药物临床安全评价及药物流行病学方面工作。先后曾但任资深临床流行病学家, 临床安全医学总监,资深医学总监,助理副总裁,副总裁,资深副总裁。现任 Astellas(安斯泰来)公司执行副总裁,主管全球药物警戒、临床安全评价、药物流行病学、药物安全风险管理, 以及安斯泰来在四十五个国家的药物警戒部门。薛松林曾担任国际药物流行病学学会董事会成员和全球发展委员会主席,美国药物研发协会流行病学专家委员会成员,中国预防医学教育理事会成员, 以及中国药物流行病学会专业委员会理事。薛松林任中国中南大学湘雅医学院客座教授。

  Songlin Xue is Executive Vice President and Head of the global Pharmacovigilance for Astellas. In this position he leads a global pharmacovigilance organization which includes pharmacovigilance operation and processes, medical safety, risk management, and epidemiology functions for clinical development compounds and for post-approval products worldwide. He is also responsible for pharmacovigilance function and staff in 45 affiliate countries. Before he joined Astellas, Dr. Xue served in a number of positions such as Senior Clinical Epidemiologist, Associate Medical Director, Medical Director, Senior Medical Director, Assistant Vice President, Vice President, and Senior Vice President in several international pharmaceutical companies including Hoffman-La Roche, Pfizer, Novartis, and Takeda.